Phase 1/2 Trial of SBT-20 In Early-stage Huntington’s Begins in Holland
May 04, 2017 08:43 am | Joana Fernandes, PhD
Stealth BioTherapeutics has started a Phase 1/2 clinical trial to investigate the safety and effectiveness of SBT-20 in patients with early-stage Huntington’s disease in the Netherlands. SBT-20 was designed to restore the proper activity of mitochondria, the cell’s powerhouses, in Huntington’s patients. Mitochondria organelles become faulty as the disease progresses. “Huntington’s disease is a fatal genetic […]
The post Phase 1/2 Trial of SBT-20 In Early-stage Huntington’s Begins in Holland appeared first on Huntington's Disease News.